Compound library

A peptide that concentrates in the inner mitochondrial membrane. It has one narrow US approval, in the ultra-rare genetic condition Barth syndrome, based on a very small trial programme under the accelerated approval route. That approval does not validate longevity, general energy, mitochondrial optimisation or wellness use.

Mitochondria-targeting peptide granted US FDA accelerated approval on 19 September 2025, solely to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. No UK marketing authorisation was identified.

A mitochondrially encoded peptide with interesting metabolic and exercise biology in cells and animals. No completed human therapeutic efficacy result was found; a Phase 2a study is now registered/recruiting.

Mitochondrial peptide with strong mechanistic/preclinical interest but no completed human therapeutic efficacy dataset yet.

An investigational GIP/GLP-1/glucagon triple agonist with strong phase 2 evidence and positive phase 3 topline results, but no marketing authorisation yet.

Investigational triple agonist. Human efficacy evidence is now substantial, including positive pivotal phase 3 results, but regulatory approval has not yet been granted.

A licensed GLP-1 medicine with extensive randomised human evidence for weight management and type 2 diabetes. Evidence depends on the product, route and indication.

GLP-1 receptor agonist with extensive phase 3 evidence. Wegovy is UK-authorised for weight management in defined populations; other semaglutide brands have different licensed indications.

A UK-licensed GIP/GLP-1 medicine with large randomised trials for weight management and type 2 diabetes. Its strongest claims are supported by substantial human evidence.

Dual GIP/GLP-1 receptor agonist with large phase 3 weight-management trials and current UK authorisation.

A long-acting GHRH analogue studied in healthy adults. It can raise GH and IGF-1 for days, but that does not establish benefits for recovery, sleep or body composition.

GH-releasing peptide, almost always paired with Ipamorelin, used for recovery, sleep and body composition.

A ghrelin-receptor agonist shown in human volunteer studies to trigger growth-hormone release. That pharmacology is real, but benefits for recovery, sleep or body composition have not been established in robust clinical outcome trials.

Growth-hormone secretagogue with direct human PK/PD evidence, but limited evidence for meaningful wellness or body-composition outcomes.

An oral ghrelin-receptor agonist that reliably raises GH and IGF-1 in humans. Longer trials found more fat-free mass, but not better strength or function, and identified glucose, fluid-retention and heart-failure concerns in some populations.

Oral growth-hormone secretagogue with substantial human pharmacology data. In older adults it increased fat-free mass without improving strength or function; safety concerns limit any simple wellness interpretation.

Sermorelin is GHRH(1-29), an older growth-hormone-releasing peptide with real human endocrine and paediatric clinical history. That does not establish modern anti-ageing, sleep, recovery or body-composition claims.

Historical GHRH(1-29) medicine/research peptide with human endocrine and paediatric growth studies; current wellness applications are much less evidenced.

A GHRH analogue with strong randomised human evidence for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That evidence does not establish it as a general weight-loss or longevity treatment.

GHRH analogue with multiple phase 3 trials for excess visceral abdominal fat in HIV-associated lipodystrophy; evidence should not be generalized to routine obesity or wellness use.

A synthetic peptide with extensive preclinical interest but only tiny, uncontrolled human studies so far. Human efficacy, validated dosing and long-term safety are not established.

Preclinical tissue-repair peptide with very limited uncontrolled human data. A randomised Phase 2 hamstring trial is recruiting, but no controlled efficacy result is available yet.

A three-amino-acid fragment of alpha-MSH with anti-inflammatory effects in cells and animal colitis models. No verified human therapeutic trial was found in this audit.

Preclinical anti-inflammatory tripeptide. Current evidence is cell and animal work rather than human therapeutic trials.

The body's own antimicrobial peptide, developed as a topical wound treatment under the name ropocamptide. A phase IIb randomised trial in venous leg ulcers did not show a significant healing benefit overall. A positive result in patients with larger ulcers came from a post hoc look at the data, which generates a question rather than answering one.

Human cathelicidin host-defence peptide studied as a topical wound treatment. Its one substantial controlled human trial, a 148-patient phase IIb study in venous leg ulcers, found no significant healing improvement across the full study population.

TB-500 is an acetylated seven-amino-acid fragment of thymosin beta-4, not the full 43-amino-acid molecule. Human trials of full-length thymosin beta-4 cannot simply be transferred to TB-500.

Synthetic Ac-LKKTETQ fragment of thymosin beta-4. Direct human efficacy, safety and pharmacokinetic evidence for the exact TB-500 fragment has not been established.

Bremelanotide (PT-141) has large randomised phase 3 evidence for acquired, generalised hypoactive sexual desire disorder in premenopausal women and is authorised for that indication in the US. That evidence does not establish use in men or other sexual problems.

Central melanocortin agonist with phase 3 efficacy and safety evidence for a specific female HSDD indication; broader libido and male-ED use is extrapolation.

A copper-binding peptide widely used in cosmetics. Mechanistic and preclinical evidence is substantial, but published clinical evidence for exact GHK-Cu anti-ageing or hair claims is much thinner than marketing often suggests.

Copper-binding peptide used in cosmetics. Evidence is route- and formulation-specific; topical clinical evidence is limited and injectable/systemic claims are not established.

A synthetic tetrapeptide usually called Epitalon or Epithalon. Human publications exist, but much of the literature mixes the exact tetrapeptide with Epithalamin, a different pineal extract, and there are no large independent trials establishing anti-ageing benefit.

Synthetic AEDG tetrapeptide with limited and difficult-to-interpret human literature. Evidence is weakened by small studies, limited independent replication and frequent conflation with the distinct pineal extract Epithalamin.

A designed peptide that, in cell and mouse experiments, disrupts an interaction between the FOXO4 and p53 proteins so that senescent "zombie" cells self-destruct. Nothing in the catalogued record is a human result.

Preclinical senolytic research peptide. Published work is in cells and mice only: there is no established human efficacy, dose, pharmacokinetics or safety.

A short peptide based on a fragment of the immune protein tuftsin. Small human studies, predominantly Russian, report anxiolytic effects in diagnosed anxiety disorders. Those studies have not been robustly replicated to modern independent standards, and they say nothing about focus, memory or general wellbeing in healthy people.

Synthetic heptapeptide studied for anxiety disorders in a small, geographically concentrated human literature. No UK marketing authorisation was identified, and everyday cognition or focus claims are not established.

A synthetic ACTH fragment with some human clinical history, mainly older Russian stroke and neurorehabilitation studies. Evidence for everyday focus, mood or cognitive enhancement is not robust.

Nootropic/neurorehabilitation peptide with limited human literature concentrated in Russian stroke research; modern wellness claims are substantially less established.

Thymosin alpha-1 (thymalfasin) has real randomised human evidence in several infectious and immune-related conditions, but results are mixed and highly indication-specific. It is not established as a general-purpose immune booster.

Immunomodulatory thymic peptide with substantial but heterogeneous human trial evidence. Some older hepatitis and critical-care studies are positive, while a large modern phase 3 sepsis trial was negative.